The gene editing and gene modulation technology firm has entered into a collaboration with an unnamed global pharma partner to develop the research tool for target identification and validation.
The company will offer the tools to offer to any future partners as part of its research services offering.
Horizon will lead the development using “a key discovery paradigm of the pharma partner,” according to the company. It also will use acquired infrastructure and optimization data.
Terry Pizzie, CEO of Horizon Discovery said, “Pooled CRISPR-Cas9 knockout screens have rapidly become an important tool in novel drug target identification and validation.”
“The co-development of this tool with a major pharma partner provides a substantive advance to Horizon’s already world-leading screening capabilities, offering our customers cutting-edge solutions not available elsewhere,” Pizzie said in a press release.
Horizon in 2017 launched its CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) screening service.